$-0.16 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG)

July 11, 2018 - By Louis Casey

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) LogoInvestors sentiment decreased to 0.84 in 2018 Q1. Its down 0.06, from 0.9 in 2017Q4. It dropped, as 27 investors sold AMAG Pharmaceuticals, Inc. shares while 55 reduced holdings. 32 funds opened positions while 37 raised stakes. 37.48 million shares or 0.65% less from 37.72 million shares in 2017Q4 were reported.
Howe & Rusling reported 202 shares or 0% of all its holdings. Numerixs Inv Tech reported 3,700 shares. Acadian Asset Mngmt Lc owns 184,682 shares. Federated Invsts Inc Pa accumulated 0% or 81,460 shares. 1.33M were reported by Fmr Ltd Liability Co. Brandes Prns L P stated it has 50,424 shares or 0.02% of all its holdings. Qs Invsts Lc reported 0.02% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Great West Life Assurance Com Can, a Manitoba – Canada-based fund reported 45,019 shares. Citadel accumulated 64,642 shares. Proshare Limited Liability Corporation owns 21,896 shares or 0% of their US portfolio. Millennium Mgmt Ltd Liability Corporation reported 0.01% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Glenmede Trust Na invested in 338 shares or 0% of the stock. Advisory Ser Limited Liability Company holds 0% or 54 shares. Geode Limited Liability Company accumulated 369,556 shares. Lpl Fin Llc reported 34,343 shares.

Since February 23, 2018, it had 0 insider purchases, and 2 insider sales for $516,016 activity. Another trade for 20,000 shares valued at $500,000 was made by HEIDEN WILLIAM K on Monday, June 4.

Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $-0.16 EPS on August, 2.They anticipate $0.24 EPS change or 60.00 % from last quarter’s $-0.4 EPS. After having $-1.59 EPS previously, AMAG Pharmaceuticals, Inc.’s analysts see -89.94 % EPS growth. The stock increased 3.87% or $0.8 during the last trading session, reaching $21.45. About 486,805 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 30.22% since July 11, 2017 and is uptrending. It has outperformed by 17.65% the S&P500.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 8 analysts covering Amag Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Amag Pharmaceuticals had 19 analyst reports since January 18, 2018 according to SRatingsIntel. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Piper Jaffray on Thursday, January 18. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, February 28 report. Cantor Fitzgerald maintained it with “Hold” rating and $17.0 target in Tuesday, February 27 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Thursday, February 1 by Cantor Fitzgerald. The firm has “Buy” rating given on Thursday, February 15 by Jefferies. The firm has “Hold” rating given on Tuesday, February 27 by Cowen & Co. Leerink Swann initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Monday, May 21 with “Hold” rating. The firm earned “Hold” rating on Wednesday, February 14 by Cantor Fitzgerald. The stock has “Neutral” rating by Janney Capital on Friday, June 15. FBR Capital maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rating on Friday, March 23. FBR Capital has “Hold” rating and $2300 target.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for women??s health, anemia management, and cancer supportive care in the United States. The company has market cap of $736.31 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

More news for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were recently published by: Globenewswire.com, which released: “Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton …” on June 18, 2018. Nasdaq.com‘s article titled: “AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®” and published on June 15, 2018 is yet another important article.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.